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Diffuse bronchiolo-alveolar cell carcinoma (BAC) with endolymphatic tumor emboli
involving whole lung ﬁelds was found in a 25-year-old male. He had a history of 6 pack
years of smoking. After a thoracoscopic lung biopsy, his condition was aggravated leading
to imminent respiratory failure. Although geﬁtinib is not usually recommended as a ﬁrst-
line chemotherapeutic drug, we decided to use it considering that the added toxicity of
conventional drugs would be fatal to him. Surprisingly, the patient showed the dramatic
improvement and was able to exercise 1 week after the treatment. The immunostainings
for p-Akt and E-cadherin were strongly positive. A deletion mutation (delE746–750) was
detected in exon 19 by sequencing. The ﬂuorescent in situ hybridization (FISH) was
negative as low trisomy suggesting that the epidermal growth factor receptor (EGFR)
mutation is a more reliable ﬁnding for prediction of the response to this novel drug, even in
a patient with unfavorable clinical characteristics such as male gender and smoker. An
EGFR–tyrosine kinase inhibitor (EGFR–TKI), either alone or combined with other
chemotherapeutic drugs, should be considered an initial therapeutic option in patients
with disseminated lung cancer requiring urgent treatment.




Figure 1 (A) A chest radiograph showing a mass-like opacity
adjacent to the right side of the cardiac border with
disseminated small nodules in both lung ﬁelds. (B) Aggravated
lung lesions after the thoracoscopic biopsy. (C) Markedly
improved diffuse BAC 1 week after the treatment with geﬁtinib.
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Geﬁtinib, an orally active epidermal growth factor recep-
tor–tyrosine kinase inhibitor (EGFR–TKI), has shown favor-
able anti-tumor activity and good tolerability in lung
cancer patients. A favorable response to this drug has been
more frequently observed in female, non-smoker, ethnic
Asians and adenocarcinoma (especially, bronchiolo-alveolar
cell carcinoma (BAC)).1,2 Responses have often led to
prompt improvement of symptoms and the disease itself.
The immediate patient response to this treatment suggests
that it might be most useful in life-threatening situations.
We report an impressive response in a young male patient
with a smoking history and lung cancer.
Case report
A previously healthy 25-year-old male was referred to our
hospital in June 2007 for the management of BAC that was
diagnosed by a thoracoscopic biopsy at a local hospital. He
visited that hospital 2 weeks previously for cough and
dyspnea of 2 months’ duration. He had a history of 6 pack
years of smoking. An initial chest PA showed a mass-like
opacity adjacent to the right side of the cardiac border with
disseminated small nodules in both lung ﬁelds (Figure 1A).
His dyspnea was aggravated after the biopsy due to the
progression of the lung cancer (Figure 1B). The dyspnea was
so severe that it was difﬁcult for him to stand up out of bed
and to eat. The PaO2 was 66.3mmHg in oxygen supplied at
10 L/min by mask. The respiratory rate was over 30min1
suggesting that respiratory failure was imminent. BAC was
conﬁrmed by the pathological examination of the obtained
lung specimen. In addition, endolymphatic tumor emboli
were found, which might explain the widespread nature of
the disease. Surprisingly, his symptoms started improving
just 3 days after treatment with geﬁtinib. The patient could
exercise 1 week after the start of treatment. The chest PA
taken 1 week later showed that the disseminated lung
lesions were remarkably improved (Figure 1C). This dra-
matic response was also demonstrated on the chest CT
performed 3 weeks later (Figure 2). The immunostainings for
p-Akt and E-cadherin were strongly positive (Figure 3A
and B). The analysis for EGFR–TK mutations (exon 18–21) by
sequencing revealed a deletion mutation (delE746–750) in
exon 19 (Figure 3C) while the ﬂuorescent in situ hybridiza-
tion (FISH) was negative as low trisomy (Figure 3D).
Discussion
The current guidelines for non-small cell lung cancer
treatment recommend that the EGFR–TKI should be used
after cytotoxic chemotherapy in unselected patients with
advanced stage disease. However, several reports showed
that treatment with geﬁtinib could achieve a high response
rate in chemotherapy-naı¨ve patients with favorable clinical
characteristics for a response3 or EGFR mutations 4,5
although the exact role of geﬁtinib, as a ﬁrst-line drug,
should be clariﬁed through randomized trials comparing
cytotoxic agents. Some reports demonstrated that geﬁtinib
could rapidly control intractable symptoms such as bronch-
orrhea and dyspnea.6,7
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Figure 2 (A) Airspace opacities of the RLL and the RML with diffuse ﬁne nodules, ground glass opacities in both lungs suggesting
diffuse-type BAC. (B) Lung cancer presenting airspace opacities of the RLL and the RML with diffuse pulmonary metastasis remarkably
improved on chest CT taken 3 weeks later.
Figure 3 (A) The immunohistochemical staining for p-Akt revealed diffuse nuclear and cytoplasm positive reaction (Cell Signaling,
1:200). (B) The strong cytoplasm membrane positivity was found with the immunohistochemical staining for E-cadherin (DAKO, 1:50).
(C) The deletion mutation (delE746–750) in exon 19 was detected by sequencing for EGFR. (D) Dual color FISH with EGFR (orange
signal) and chromosome 7 (CEP7, green signal) probes showed FISH negative as low trisomy.
S.Y. Jeon et al.98In some cases, such as the one reported here with
imminent respiratory failure due to disseminated lung
cancer, emergency intervention is required. Under these
circumstances, the added toxicity of chemotherapeutic
agents could increase the morbidity and mortality of
patients. Consideration of EGFR–TKI as an initial agent
seems to be reasonable due to the reported prompt and
dramatic responses.
Many studies including some prospective reports showed
that EGFR mutations, especially the exon 19 deletion, are
closely related to the clinical response to EGFR–TKI.1,2 In
addition, several studies have suggested that the EGFR gene
copy number by FISH is a possible predictor of sensitivity toEGFR–TKI.8 Although our patient had the unfavorable
clinical characteristics such as male gender and smoker,
with regard to response to EGFR–TKI, his remarkable response
could be explained by the EGFR deletion mutation at exon 19
and positive immunohistochemical stainings for p-Akt 9 and
E-cadherin.10 However, the gene ampliﬁcation by FISH was
negative; this suggests that the EGFR mutation may be a more
reliable factor for prediction of response to EGFR–TKI
treatment, consistent with the report by Sone et al.11
EGFR–TKI, either alone or in combination with other
chemotherapeutic drugs, should be considered as an initial
therapeutic option in patients with disseminated lung
cancer requiring urgent management.
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